epigenetics-neurodegeneration

epigenetics-neurodegeneration

Introduction

Epigenetics In Neurodegeneration is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes. PMID: 34830163

Overview

Epigenetics refers to heritable changes in gene expression that occur without alterations to the underlying DNA sequence. In the central [@tracing]
nervous system, epigenetic are essential for neuronal differentiation, synaptic plasticity, memory formation, and the [@role]
maintenance of neuronal identity throughout life. Dysregulation of the epigenetic landscape has emerged as a critical contributor to the [@exploring]
pathogenesis of neurodegenerative, including Alzheimer's disease, [Parkinson's disease](/diseases/parkinsons-disease), amyotrophic lateral sclerosis, [@hyperglycaemiainduced]
frontotemporal dementia, and Huntington's disease.[@foxn] [@smith2015]

Five principal epigenetic govern chromatin state and gene regulation: (1) DNA methylation and hydroxymethylation, (2) histone [^7]
post-translational modifications, (3) chromatin remodeling, (4) non-coding RNA regulation, and (5) RNA modifications. These [^8]
operate in concert to control access to genetic information, and their perturbation in [neurons](/entities/neurons) leads to aberrant expression of genes [^9]
involved in protein aggregation, neuroinflammation, synaptic dysfunction, and [apoptosis](/entities/apoptosis) [@foxn]. [^10]

epigenetics-neurodegeneration

Introduction

Epigenetics In Neurodegeneration is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes. PMID: 34830163

Overview

Epigenetics refers to heritable changes in gene expression that occur without alterations to the underlying DNA sequence. In the central [@tracing]
nervous system, epigenetic are essential for neuronal differentiation, synaptic plasticity, memory formation, and the [@role]
maintenance of neuronal identity throughout life. Dysregulation of the epigenetic landscape has emerged as a critical contributor to the [@exploring]
pathogenesis of neurodegenerative, including Alzheimer's disease, [Parkinson's disease](/diseases/parkinsons-disease), amyotrophic lateral sclerosis, [@hyperglycaemiainduced]
frontotemporal dementia, and Huntington's disease.[@foxn] [@smith2015]

Five principal epigenetic govern chromatin state and gene regulation: (1) DNA methylation and hydroxymethylation, (2) histone [^7]
post-translational modifications, (3) chromatin remodeling, (4) non-coding RNA regulation, and (5) RNA modifications. These [^8]
operate in concert to control access to genetic information, and their perturbation in [neurons](/entities/neurons) leads to aberrant expression of genes [^9]
involved in protein aggregation, neuroinflammation, synaptic dysfunction, and [apoptosis](/entities/apoptosis) [@foxn]. [^10]

The reversibility of epigenetic modifications makes them particularly attractive therapeutic targets. Unlike genetic mutations, epigenetic [@yadav2025]
changes can potentially be pharmacologically corrected, offering new avenues for disease-modifying treatments in neurodegeneration.[@tracing] [@sokpor2017]

DNA Methylation and Hydroxymethylation

Mechanisms of DNA Methylation

DNA methylation is the covalent addition of a methyl group to the 5-carbon position of cytosine, primarily at CpG dinucleotides, catalyzed [@frost2014]
by DNA methyltransferases (DNMTs). The methyl donor is S-adenosyl-L-methionine (SAM). In the brain, approximately 75-80% of CpG sites are [@salta2016]
methylated, with distinct patterns in neurons versus glial cells. DNA methylation at gene promoters typically represses transcription by [@horvath2013]
recruiting methyl-CpG binding domain (MBD) and preventing transcription factor binding [@tracing]. [@shireby2020]

Active DNA demethylation occurs through the ten-eleven translocation (TET) enzymes, which sequentially oxidize 5-methylcytosine (5mC) to [@magistri2016] PMID: 36432638
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). Notably, 5hmC is highly enriched in the brain — [@nakamura2025]
approximately 10-fold higher than in peripheral tissues — and is particularly abundant in neurons, where it marks active genes and
enhancers.[@role]

DNA Methylation Changes in Alzheimer's Disease

Large-scale epigenome-wide association studies (EWAS) have identified widespread DNA methylation alterations in Alzheimer's disease brains. The landmark 2014 studies by De Jager et al. and Lunnon et al., published simultaneously in Nature Neuroscience, identified methylation changes at 71 CpG sites significantly associated with AD pathology burden, including loci at ANK1, BIN1, RHBDF2, ABCA7, and other genes. The ANK1 locus showed consistent hypermethylation in cortical regions but not in the cerebellum, a region relatively spared in AD.4,5</a>

A 2021 meta-analysis by Smith et al. combining six EWAS datasets (N=1,453 individuals) identified 220 CpGs associated with AD neuropathology
across cortex, annotated to 121 genes, of which 84 had not been previously reported.[@smith2015]

Specific AD-related genes show characteristic methylation changes:

• [APP](/entities/app-protein): Hypomethylation of the APP gene promoter has been consistently reported in AD brains, leading to elevated APP expression and enhanced [amyloid-beta](/proteins/amyloid-beta)//amyloid production
• PSEN1: Reduced methylation in the 5-prime flanking region in AD cortex, with an inverse correlation between lower methylation and increased [presenilin-1](/entities/psen1)//presenilin-1) protein levels during disease progression
• **[BACE1](/entities/bace1) demonstrated that SNCA intron 1 methylation was reduced in substantia nigra, putamen, and cortex of sporadic PD patients, with hypomethylation leading to increased alpha-synuclein expression. The TET1 enzyme acts as a repressor of SNCA by binding intron 1 regions, and postmortem PD brains show reduced TET1 levels[^7]
• PGC-1alpha: Hypermethylation of the PGC-1alpha promoter, a master regulator of mitochondrial biogenesis, has been reported in PD, contributing to mitochondrial dysfunction
• EWAS meta-analysis of whole blood confirmed SLC7A11 hypermethylation and identified novel differentially methylated CpGs near LPIN1 in PD

DNA Methylation in ALS and FTD

The C9orf72 hexanucleotide repeat expansion, the most common genetic cause of both ALS and FTD, shows striking epigenetic regulation:

• C9orf72 promoter hypermethylation occurs in approximately 30% of expansion carriers
• Hypermethylation is associated with transcriptional silencing of mutant C9orf72, reduced RNA foci and dipeptide repeat (DPRs, and diminished pathological inclusions
• Neuroimaging reveals that [hippocampus](/brain-regions/hippocampus), frontal cortex, and thalamus are relatively protected in hypermethylated carriers
• C9orf72 promoter hypermethylation is associated with longer survival in C9orf72-FTD patients and later age of onset in ALS, representing a neuroprotective epigenetic modification[^8]

Histone Modifications

Overview of Histone Marks in the Brain

Histones are subject to extensive post-translational modifications including acetylation, methylation, phosphorylation, ubiquitination,
SUMOylation, lactylation, and crotonylation. These modifications form a "histone code" that governs chromatin accessibility and gene
expression. In neurons, [histone modifications](/entities/histone-modifications) are dynamically regulated during learning, memory formation, and synaptic plasticity, and
their dysregulation contributes to neurodegeneration.[^9]

Histone Acetylation

Histone acetylation, catalyzed by histone acetyltransferases (HATs) and removed by histone deacetylases (HDACs, see [protein acetylation and
[HDAC](/entities/hdac-enzymes), generally promotes an open chromatin configuration and active gene transcription [@role]
.

In Alzheimer's Disease:

• The landmark study by Nativio et al. (2018) in Nature Neuroscience revealed that while normal aging leads to progressive H4K16ac enrichment near genes linked to aging and neuroprotection, AD brains show dramatic losses of H4K16ac at these same loci. This work proposed that AD is not simply accelerated aging but a dysregulated aging process with disease-specific chromatin alterations[^10]
• A follow-up multi-omics study (Nativio et al., 2020, Nature Genetics) identified gains in H3K27ac and H3K9ac specific to AD, linked to transcription and chromatin pathways
• Hippocampal neurons in AD show specific loss of H4K12ac, leading to silencing of synaptic plasticity-related genes
• Single-cell epigenomic analysis has revealed that abnormal H3K27ac distribution in neurons of AD patients precedes amyloid//amyloid plaque formation

• [alpha-synuclein//alpha has been shown to directly associate with histones and promote their acetylation, potentially contributing to [transcriptional dysregulation

Histone Methylation

Histone methylation involves the addition of one to three methyl groups to lysine or arginine residues, with effects on gene expression
depending on the specific residue and degree of methylation [@exploring].

Key marks altered in neurodegeneration:

• H3K4me3 (activating mark): Enriched at the SNCA promoter in sporadic PD iPSC-derived dopaminergic neurons. In postmortem AD brains and tau] mouse models, H3K4me3 was significantly increased, leading to upregulation of neurodegeneration-implicated genes
• H3K27me3 (repressive mark): Deposited by the Polycomb Repressive Complex 2 (PRC2), including EZH2. Abnormal H3K27me3 distribution controls gene expression including alpha-synuclein in substantia nigra neurons of PD patients
• H3K9me3 (heterochromatin mark): H3K9me3-landscaped genes in AD are associated with synaptic transmission, neuronal differentiation, and cell motility, including BDNF, GABBR1, and GABBR2. Age-related increases in H3K9me3 in the hippocampus contribute to repression of plasticity genes9,11</a>

Histone Phosphorylation

Histone phosphorylation, particularly at H3S10 and H3S28, is involved in chromatin condensation, DNA damage response, and transcriptional
activation. Increased H3 phosphorylation has been documented in AD brains, potentially reflecting aberrant neuronal cell cycle re-entry — PMID: 35813941
a known phenomenon in vulnerable neurons in AD [@hyperglycaemiainduced].

Chromatin Remodeling

ATP-Dependent Chromatin Remodeling Complexes

ATP-dependent chromatin remodeling complexes use the energy of ATP hydrolysis to reposition, eject, or restructure nucleosomes, controlling
gene accessibility. The BRG1/BRM-associated factor (BAF or mSWI/SNF) complex, comprising at least 15 subunits (~2 MDa), plays a critical
role in neuronal development, maturation, and function [@smith2015]
.

Neural progenitor-specific BAF complexes (npBAF) are essential for controlling neural progenitor cell division, while neuron-specific BAF
(nBAF) complexes are necessary for the maturation of postmitotic neuronal phenotypes. Subunit switching from npBAF to nBAF is a fundamental
mechanism of neuronal differentiation.[@sokpor2017]

Tau-Induced Chromatin Relaxation

Frost et al. (2014) demonstrated in Nature Neuroscience that tau//tau promotes neurodegeneration through global chromatin
relaxation. Using Drosophila and mouse models, they showed widespread loss of heterochromatin in tauopathies, with oxidative stress
and DNA damage serving as a mechanistic link between tau and heterochromatin loss. Genetic rescue of heterochromatin loss substantially
reduced neurodegeneration, establishing chromatin relaxation as a causal mechanism in tau-mediated neuronal death.[@frost2014]

Non-Coding RNAs in Neurodegeneration

MicroRNAs

MicroRNAs (miRNAs) are small non-coding RNAs (~22 nucleotides) that regulate gene expression post-transcriptionally by binding to the
3'-untranslated regions of target mRNAs (see [non-coding RNA in neurodegeneration). Multiple miRNAs are dysregulated in neurodegenerative
[^7].

Key miRNAs in Alzheimer's Disease:

• miR-132/212 cluster: Consistently downregulated across AD studies. miR-132 is involved in pro-survival, anti-inflammatory, and memory-promoting functions. Deletion of miR-132/212 in mice increases tau//tau expression, phosphorylation, and accumulation. Salta et al. (2016) showed that miR-132 loss de-represses ITPKB, aggravating both amyloid and tau pathology[@salta2016]
• miR-29b, miR-181c, miR-15b, miR-146a, miR-107: Consistently downregulated across at least two independent studies
• Diagnostic accuracy of circulating miRNAs for AD yields a combined AUC of 0.88, with pooled sensitivity of 0.80 and specificity of 0.83

• miR-7 and miR-153 regulate [alpha-synuclein//alpha expression
• miR-34b/c is downregulated in PD brains in motor and pre-motor areas

Long Non-Coding RNAs

Long non-coding RNAs (lncRNAs, >200 nucleotides) regulate gene expression through chromatin modulation, post-transcriptional regulation, and
protein complex organization [^8].

Key lncRNAs in neurodegeneration:

• BACE1-AS: The antisense transcript of BACE1 upregulates BACE1 through formation of an RNA duplex that increases BACE1 mRNA stability, enhancing amyloidogenic processing — one of the best-characterized lncRNA in AD
• NEAT1: Upregulated in AD and PD; involved in paraspeckle formation and inflammatory gene regulation
• HOTAIR: Increased in AD; promotes tau//tau phosphorylation through regulation of chromatin
• MALAT1: Altered in multiple neurodegenerative conditions; regulates synaptic gene expression

Epigenetic Clock and Brain Aging

The Horvath Clock and Brain-Specific Clocks

The epigenetic clock, developed by Steve Horvath in 2013, uses DNA methylation patterns at 353 CpG sites to estimate biological age with
remarkable accuracy (correlation with chronological age of 0.97, median absolute error of 2.9 years). The concept that epigenetic age can
deviate from chronological age — termed "epigenetic age acceleration" — has profound implications for understanding neurodegeneration as a PMID: 24905038
disease of accelerated biological aging.[@horvath2013]

However, standard epigenetic clocks perform suboptimally in brain tissue. Shireby et al. (2020) developed DNAmClockCortical, a
brain-specific epigenetic clock built from over 1,000 human cortex samples, which dramatically outperforms existing clocks for cortical age
prediction.[@shireby2020]

Epigenetic Age Acceleration in Neurodegenerative Disease

Multiple epigenetic clocks have been associated with AD pathology. The Cortical clock shows substantially stronger associations: each
standard deviation increase in Cortical age corresponds to a 90% greater likelihood of pathologic AD, compared to approximately 30% for the
Hannum, Horvath, and PhenoAge clocks [^9].

Recent cell-type-specific analyses (2024-2025) have revealed that glial cells — particularly [microglia](/cell-types/microglia-neuroinflammation) — age
fastest in AD patients, suggesting that accelerated aging of specific cell types plays a critical role in neurodegeneration [^10].

Key Epigenetic Enzymes

DNA Methyltransferases (DNMTs)

• DNMT1: Maintenance methyltransferase that copies methylation patterns during DNA replication. DNMT1 is indispensable during embryonic development and plays a key role in chromatin structure, neuronal survival, and cell cycle regulation. Mutations in DNMT1 cause hereditary sensory and autonomic neuropathy type 1E (HSAN1E)
• DNMT3A/3B: De novo methyltransferases that establish new methylation patterns. DNMT3A is highly expressed in the adult brain and is critical for synaptic plasticity and long-term memory formation

TET Enzymes

• TET1: Acts as a repressor of SNCA by binding intron 1 regions; reduced in postmortem PD brains
• TET2: Implicated in age-related neuroinflammation; TET2-mediated changes modulate microglial//microglia activation
• TET3: Overexpression significantly attenuates neurodegeneration in AD mouse models, reducing Amyloid-Beta//amyloid accumulation and tau//tau hyperphosphorylation

Histone Acetyltransferases (HATs)

• CBP/p300: The CREB-binding protein is critical for memory formation. Reduced CBP activity is implicated in AD and [Huntington's disease, with polyglutamine-expanded [huntingtin](/entities/huntingtin-protein)//huntingtin) sequestering CBP
• Tip60: Member of the MYST family; loss of Tip60 in neurons is associated with increased apoptosis and tau pathology

Histone Deacetylases (HDACs)

• HDAC2: Elevated in AD brains; negatively regulates synaptic plasticity genes
• HDAC3: Involved in memory regulation and is a therapeutic target
• HDAC6: A cytoplasmic deacetylase that deacetylates tubulin and Hsp90. HDAC6 inhibition restores axonal transport, promotes tau//tau clearance, and reduces neuroinflammation, making it one of the most actively pursued targets in neurodegeneration
• SIRT1: Activates alpha and reduces Amyloid-Beta//amyloid generation; SIRT1 levels are reduced in AD cortex

EZH2 (Enhancer of Zeste Homolog 2)

The catalytic subunit of PRC2 that trimethylates H3K27. [EZH2 modulates [microglial//microglia activation, triggering release of
pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha). The EZH2 inhibitor GSK-343 has shown neuroprotective properties against
[dopaminergic degeneration in PD models by regulating the NF-kappaB/IkappaB-alpha pathway.[@yadav2025]

Therapeutic Approaches

HDAC Inhibitors

HDAC inhibitors represent the most advanced class of epigenetic therapeutics for neurodegeneration:

Pan-HDAC inhibitors:

• Vorinostat (SAHA): FDA-approved for cutaneous T-cell lymphoma; improves cognitive function in AD mouse models by increasing H4K12 acetylation and enhancing memory consolidation gene expression. Currently in clinical trials for AD
• Sodium phenylbutyrate: Studied in combination with tauroursodeoxycholic acid (AMX0035/Relyvrio) for ALS
• Valproic acid: Long-used anticonvulsant with HDAC inhibitory properties; epidemiological studies suggest potential neuroprotective effects

• Tubastatin A: Restores axonal transport and reduces tau//tau phosphorylation in preclinical models
• TN-301: Phase I clinical trial showed good tolerability with adverse event frequency comparable to placebo
• T-518: Novel oral HDAC6 inhibitor showing therapeutic potential in AD and tauopathy mouse models[@tracing]

BET Bromodomain Inhibitors

BET (BRD2, BRD3, BRD4) function as "readers" of acetylated histones and interact with transcription factors to regulate proinflammatory gene expression:

• JQ1: A thienotriazolodiazepine BET inhibitor that reduces neuroinflammation and tau//tau phosphorylation at Ser396 in the 3xTg mouse model of AD. JQ1 suppresses LPS-induced upregulation of pro-inflammatory cytokines in [microglia//microglia[@magistri2016]

CRISPR Epigenome Editing

A rapidly advancing frontier involves CRISPR-based epigenome editing for neurological disorders:

• CRISPR-dCas9-DNMT3A: Used to silence the tau] gene, achieving significantly lower tau levels in treated neurons
• RENDER platform (2025): Transient delivery of programmable epigenetic repressors/activators as ribonucleoprotein complexes; demonstrated durable epigenetic silencing in human stem cell-derived neurons and reduced [tau protein](/entities/tau-protein)//tau levels
• SNCA-targeted therapy: Lentiviral dCas9-DNMT3A systems reduced alpha-synuclein//alpha expression in [substantia nigra in a 2025 preclinical study[@nakamura2025]

Disease-Specific Epigenetic Connections

MAPT Promoter Methylation in Tauopathies

The MAPT gene], encoding tau protein//tau, is subject to epigenetic regulation through promoter and intron methylation:

• In progressive supranuclear palsy, CpG1 in MAPT intron 0 shows significant hypomethylation in affected frontal cortices compared to controls, correlating with increased MAPT mRNA levels
• This hypomethylation is specific to affected brain regions (frontal cortex) and is not observed in occipital cortices or other tauopathies
• PSEN1 mutations in familial AD influence MAPT methylation, suggesting crosstalk between amyloid and tau pathways

SNCA Methylation in Parkinson's Disease

The SNCA gene, encoding [alpha-synuclein//alpha, has a well-characterized methylation-dependent transcriptionally active region in intron 1:

• Hypomethylation of SNCA intron 1 in sporadic PD brains leads to increased alpha-synuclein expression[^7]
• Chronic MPTP exposure alters intron 1 methylation in mouse models, providing evidence for toxin-induced epigenetic modulation
• SNCA-targeted epigenome therapy using dCas9-DNMT3A has reduced alpha-synuclein in substantia nigra experimentally

C9orf72 Methylation in ALS/FTD

The C9orf72 hexanucleotide repeat expansion (GGGGCC) shows a remarkable epigenetic paradox:

• Promoter hypermethylation in ~30% of expansion carriers leads to transcriptional silencing
• This silencing is neuroprotective: hypermethylated carriers show reduced RNA foci, reduced DPR levels, preserved brain volume on neuroimaging, and longer survival[^8]

Recent Research

Single-cell epigenomics (2024-2025): Single-cell ATAC-seq and methylation profiling have revealed that microglia//microglia and [astrocytes](/entities/astrocytes) show the most pronounced epigenetic age acceleration in AD, preceding neuronal loss and suggesting that glial epigenetic dysfunction is an early event. PMID: 34239129

5hmC and TET3 in AD (2025): Profiling of 1,079 brains identified 2,821 differentially hydroxymethylated regions in AD, with TET3 overexpression attenuating neurodegeneration.[@role]

Novel histone modifications (2024): Discovery of histone lactylation and crotonylation alterations in AD brains, expanding the repertoire of epigenetic marks implicated in neurodegeneration.

CRISPR epigenome editing advances (2025): The RENDER platform and virus-like particle delivery of CRISPR epigenome editors demonstrated durable gene silencing in neurons, with applications to tau and alpha-synuclein reduction.[@nakamura2025]

External Links

• EWAS Atlas - Epigenome-Wide Association Studies
• Roadmap Epigenomics Project
• ENCODE Project

See Also

bfe67bb53c3c532ef4237fa3323691ae27404769

Background

The study of Epigenetics In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• FOXN1 immunodeficiency detected by TREC-based newborn screening - A challenge of management? (2026 Jun) - Immunology letters
• Tracing the threads: How toxic metals contribute to neurodegeneration. (2026 Jun) - IBRO neuroscience reports
• Role of glycolysis-mediated histone lactylation in microglial activation and progression of neurodegenerative . (2026 May) - Experimental neurology
• Exploring Sex-Based Mechanisms of Inflammation and Neurodegeneration in Multiple Sclerosis. (2026 Apr) - Biological research for nursing
• Hyperglycaemia-induced metabolic stress and epigenetic imprinting in the inflammatory pathogenesis of diabetic neuropathy. (2026 Apr) - Diabetes research and clinical practice

Pathway Diagram

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions
• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy
• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury
• BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data
• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions
• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy
• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury
• BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data

References

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 18 references |
| Replication | 33% |
| Effect Sizes | 50% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 75% |

Overall Confidence: 62%